Enalapril
- Generic Name
- Enalapril
- Brand Names
- Epaned, Vaseretic, Vasotec, Aqumeldi
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 75847-73-3
- Unique Ingredient Identifier
- 69PN84IO1A
- Background
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...
- Indication
Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction
- Associated Therapies
- -
Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype
- Conditions
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT02135263
- Locations
- 🇩🇰
Department of Clinical Pharmacology, Bispebjerg University Hospital, Copenhagen, Denmark
Prevention of Anthracycline-induced Cardiotoxicity
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 268
- Registration Number
- NCT01968200
- Locations
- 🇮🇹
European Institute of Oncology, Milan, Italy
Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- The University of The West Indies
- Target Recruit Count
- 30
- Registration Number
- NCT01891292
- Locations
- 🇯🇲
Sickle Cell Unit, Kingston, Jamaica
CSPPT- Chronic Kidney Diseases Study
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Registration Number
- NCT01871740
- Locations
- 🇨🇳
Lianyungang Center for Advanced Research in Cardiovascular Diseases, Lianyungang, Jiangsu, China
🇨🇳Anqing Branch, Anhui Institute of Biomedical Research, Anqing, Anhui, China
Mitigation of Radiation Pneumonitis and Fibrosis
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 50
- Registration Number
- NCT01754909
- Locations
- 🇺🇸
Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States
🇺🇸Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States
🇺🇸VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States
Bevacizumab vs Dacarbazine in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01705392
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Ministry of Health, Sri Lanka
- Target Recruit Count
- 200
- Registration Number
- NCT01624064
- Locations
- 🇱🇰
General (Teaching) Hospital, Anuradhapura, Anuradhapura, North Central, Sri Lanka
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 71
- Registration Number
- NCT01411735
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 208
- Registration Number
- NCT01151410
- Locations
- 🇹🇷
Novartis Investigative Site, Ankara, Turkey
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01115946
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.